Bal Pharma per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹4.54₹3.95₹4.56₹4.94₹1.67
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹4.54₹3.95₹4.56₹4.96₹1.68
₹51.65₹51.65₹48.63₹43.85₹40.66
₹210.04₹195.76₹190.37₹214.64₹193.89
—₹19.37₹13.03₹208.29₹14.67
₹7.71₹7.71₹13.03₹208.29₹14.67
—₹1.20₹0.00₹0.00₹0.00
1.61.61.61.61.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALPHARMA₹86.17

Bal Pharma Limited

· Pharma & Health
₹ CrorePeersALPAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹137 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS1.674.944.563.954.54
Diluted EPS1.684.964.563.954.54
Book Value per Share40.6643.8548.6351.6551.65
Revenue per Share193.89214.64190.37195.76210.04
Cash Flow per Share14.67208.2913.0319.37—
Free Cash Flow per Share14.67208.2913.037.717.71
Dividends per Share0.000.000.001.20—
Shares Outstanding (cr)1.61.61.61.61.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.